Common variants associated with changes in levels of circulating free fatty acids after administration of glucose-insulin-potassium (GIK) therapy in the IMMEDIATE trial

Pharmacogenomics Journal

Volumn 17, Issue 1, 2017, Pages 76-83

  Ellis, K L ^a,b   Zhou, Y ^c   Rodriguez Murillo, L ^a   Beshansky, J R ^d,e   Ainehsazan, E ^a   Selker, H P ^d   Huggins, G S ^f   Cupples, L A ^c   Peter, I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e REGIS COLLEGE   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; POTASSIUM; BIOLOGICAL MARKER; CARDIOPLEGIC AGENT; DUAL SPECIFICITY PHOSPHATASE; DUSP26 PROTEIN, HUMAN; FABP12 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; GLUCOSE-INSULIN-POTASSIUM CARDIOPLEGIC SOLUTION; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; MYO-INOSITOL-1 (OR 4)-MONOPHOSPHATASE; PHOSPHATASE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DUSP26 GENE; EPIGENETICS; FABP12 GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HEART EJECTION FRACTION; HUMAN; IMPA1 GENE; LINGO2 GENE; MAJOR CLINICAL STUDY; MALE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; CARDIAC MUSCLE; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; GENOTYPE; GLYCOLYSIS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHARMACOGENETIC VARIANT; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; BIOMARKERS; CARDIOPLEGIC SOLUTIONS; DUAL-SPECIFICITY PHOSPHATASES; FATTY ACID-BINDING PROTEINS; FATTY ACIDS, NONESTERIFIED; FEMALE; GENOTYPE; GLUCOSE; GLYCOLYSIS; HUMANS; INSULIN; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; MYOCARDIUM; PHARMACOGENOMIC VARIANTS; PHENOTYPE; PHOSPHORIC MONOESTER HYDROLASES; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84949218414     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.84     Document Type: Article

References (71)

1. van der Vusse GJ, Glatz JF, Stam HC, Reneman RS. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 1992; 72: 881-940
2. Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J Clin Invest 1988; 82: 2017-2025
3. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999; 99: 578-588
4. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634-641
5. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 1993; 264: 135-144
6. Heusch G. Hibernating myocardium. Physiol Rev 1998; 78: 1055-1085
7. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100: 1230-1239
8. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000; 49: 1231-1238
9. Apstein CS, Gravino FN, Haudenschild CC. Determinants of a protective effect of glucose and insulin on the ischemic myocardium. Effects on contractile function, diastolic compliance, metabolism, and ultrastructure during ischemia and reperfusion. Circ Res 1983; 52: 515-526
10. Cave AC, Ingwall JS, Friedrich J, Liao R, Saupe KW, Apstein CS et al. ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation 2000; 101: 2090-2096
11. Eberli FR, Weinberg EO, Grice WN, Horowitz GL, Apstein CS. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res 1991; 68: 466-481
12. Vanoverschelde JL, Janier MF, Bakke JE, Marshall DR, Bergmann SR. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. Am J Physiol 1994; 267: H1785-H1794
13. Selker HP, Beshansky JR, Griffith JL, D'Agostino RB, Massaro JM, Udelson JE et al. Study design for the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial: A double-blind randomized controlled trial of intravenous glucose, insulin, and potassium for acute coronary syndromes in emergency medical services. Am Heart J 2012; 163: 315-322
14. Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D'Agostino RB et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA 2012; 307: 1925-1933
15. Lemaitre RN, Tanaka T, Tang W, Manichaikul A, Foy M, Kabagambe EK et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet 2011; 7: e1002193
16. Wu JH, Lemaitre RN, Manichaikul A, Guan W, Tanaka T, Foy M et al. Genome-wide association study identifies novel loci associated with concentrations of four plasma phospholipid fatty acids in the de novo lipogenesis pathway: results from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2013; 6: 171-183
17. Ellis KL, Zhou Y, Beshansky JR, Ainehsazan E, Yang Y, Selker HP et al. Genetic variation at glucose and insulin trait loci and response to glucose-insulinpotassium (GIK) therapy: the IMMEDIATE trial. Pharmacogenomics J 2014; 15: 55-62
18. Ellis KL, Zhou Y, Beshansky JR, Ainehsazan E, Selker HP, Cupples LA et al. Genetic modifiers of response to glucose-insulin-potassium (GIK) infusion in acute coronary syndromes and associations with clinical outcomes in the IMMEDIATE Trial. Pharmacogenomics J 2015; 15: 488-495
19. Krebs M, Stingl H, Nowotny P, Weghuber D, Bischof M, Waldhausl W et al. Prevention of in vitro lipolysis by tetrahydrolipstatin. Clin Chem 2000; 46: 950-954
20. Voight BF, Kang HM, Ding J, Palmer CD, Sidore C, Chines PS et al. The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet 2012; 8: e1002793
21. Grove ML, Yu B, Cochran BJ, Haritunians T, Bis JC, Taylor KD et al. Best practices and joint calling of the HumanExome BeadChip: The CHARGE Consortium. PLoS One 2013; 8: e68095
22. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909
23. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 2005; 95: 221-227
24. Zhang W, Gamazon ER, Zhang X, Konkashbaev A, Liu C, Szilagyi KL et al. SCAN database: facilitating integrative analyses of cytosine modification and expression QTL. Database (Oxford) 2015; 2015. e-pub ahead of print March 27 2015.doi: 10.1093/database/bav025
25. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 2013; 14: 128
26. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74
27. Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS. Glucose-insulinpotassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 2000; 14: 615-623
28. Opie LH, Bruyneel K, Owen P. Effects of glucose, insulin and potassium infusion on tissue metabolic changes within first hour of myocardial infarction in the baboon. Circulation 1975; 52: 49-57
29. Stanley AW Jr, Moraski RE, Russell RO, Rogers WJ, Mantle JA, Kreisberg RA et al. Effects of glucose-insulin-potassium on myocardial substrate availability and utilization in stable coronary artery disease. Studies on myocardial carbohydrate, lipid and oxygen arterial-coronary sinus differences in patients with coronary artery disease. Am J Cardiol 1975; 36: 929-937
30. Rogers WJ, Stanley AW Jr, Breinig JB, Prather JW, McDaniel HG, Moraski RE et al. Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion. Am Heart J 1976; 92: 441-454
31. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 2009; 54: 1637-1646
32. Ackerman L, Freeman ML, Pacold I, Barnes WE, Johnson B, Reid RW et al. Effect of acute postinfusion lipemia and free fatty acids on myocardial contractility: assessment with radionuclide ventriculography. Eur J Nucl Med 1986; 12: 201-204
33. Nielsen R, Norrelund H, Kampmann U, Kim WY, Ringgaard S, Schar M et al. Failing heart of patients with type 2 diabetes mellitus can adapt to extreme short-term increases in circulating lipids and does not display features of acute myocardial lipotoxicity. Circ Heart Fail 2013; 6: 845-852
34. Havmoeller R, Reinier K, Teodorescu C, Ahmadi N, Kwok D, Uy-Evanado A et al. Elevated plasma free fatty acids are associated with sudden death: a prospective community-based evaluation at the time of cardiac arrest. Heart Rhythm 2014; 11: 691-696
35. Williams MJ, Almen MS, Fredriksson R, Schioth HB. What model organisms and interactomics can reveal about the genetics of human obesity. Cell Mol Life Sci 2012; 69: 3819-3834
36. Vilarino-Guell C, Wider C, Ross OA, Jasinska-Myga B, Kachergus J, Cobb SA et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics 2010; 11: 401-408
37. Wu YW, Prakash KM, Rong TY, Li HH, Xiao Q, Tan LC et al. Lingo2 variants associated with essential tremor and Parkinson's disease. Hum Genet 2011; 129: 611-615
38. Vuillaume ML, Naudion S, Banneau G, Diene G, Cartault A, Cailley D et al. New candidate loci identified by array-CGH in a cohort of 100 children presenting with syndromic obesity. Am J Med Genet A 2014; 164: 1965-1975
39. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42: 937-948
40. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42: 579-589
41. Pinent M, Hackl H, Burkard TR, Prokesch A, Papak C, Scheideler M et al. Differential transcriptional modulation of biological processes in adipocyte triglyceride lipase and hormone-sensitive lipase-deficient mice. Genomics 2008; 92: 26-32
42. Hansson O, Donsmark M, Ling C, Nevsten P, Danfelter M, Andersen JL et al. Transcriptome and proteome analysis of soleus muscle of hormone-sensitive lipase-null mice. J Lipid Res 2005; 46: 2614-2623
43. Albert JS, Yerges-Armstrong LM, Horenstein RB, Pollin TI, Sreenivasan UT, Chai S et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. N Engl J Med 2014; 370: 2307-2315
44. Smathers RL, Petersen DR. The human fatty acid-binding protein family: evolutionary divergences and functions. Hum Genomics 2011; 5: 170-191
45. Liu RZ, Li X, Godbout R. A novel fatty acid-binding protein (FABP) gene resulting from tandem gene duplication in mammals: transcription in rat retina and testis. Genomics 2008; 92: 436-445
46. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-413
47. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH et al. Circulating adipocytefatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007; 115: 1537-1543
48. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 1796-1802
49. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007; 30: 2667-2672
50. Ota H, Furuhashi M, Ishimura S, Koyama M, Okazaki Y, Mita T et al. Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens 2012; 25: 1124-1130
51. Fuseya T, Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Mita T et al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol 2014; 13: 126
52. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006; 103: 6970-6975
53. Damcott CM, Moffett SP, Feingold E, Barmada MM, Marshall JA, Hamman RF et al. Genetic variation in fatty acid-binding protein-4 and peroxisome proliferatoractivated receptor gamma interactively influence insulin sensitivity and body composition in males. Metabolism 2004; 53: 303-309
54. Khalyfa A, Bhushan B, Hegazi M, Kim J, Kheirandish-Gozal L, Bhattacharjee R et al. Fatty-acid binding protein 4 gene variants and childhood obesity: potential implications for insulin sensitivity and CRP levels. Lipids Health Dis 2010; 9: 18
55. Wang J, Tang J, Wang B, Song J, Liu J, Wei Z et al. FABP4: a novel candidate gene for polycystic ovary syndrome. Endocrine 2009; 36: 392-396
56. Toker L, Bersudsky Y, Plaschkes I, Chalifa-Caspi V, Berry GT, Buccafusca R et al. Inositol-related gene knockouts mimic lithium's effect on mitochondrial function. Neuropsychopharmacology 2014; 39: 319-328
57. Daniele G, Eldor R, Merovci A, Clarke GD, Xiong J, Tripathy D et al. Chronic reduction of plasma free fatty acid improves mitochondrial function and wholebody insulin sensitivity in obese and type 2 diabetic individuals. Diabetes 2014; 63: 2812-2820
58. Vasudevan SA, Skoko J, Wang K, Burlingame SM, Patel PN, Lazo JS et al. MKP-8, a novel MAPK phosphatase that inhibits p38 kinase. Biochem Biophys Res Commun 2005; 330: 511-518
59. Takagaki K, Shima H, Tanuma N, Nomura M, Satoh T, Watanabe M et al. Characterization of a novel low-molecular-mass dual specificity phosphatase-4 (LDP-4) expressed in brain. Mol Cell Biochem 2007; 296: 177-184
60. Hu Y, Mivechi NF. Association and regulation of heat shock transcription factor 4b with both extracellular signal-regulated kinase mitogen-activated protein kinase and dual-specificity tyrosine phosphatase DUSP26. Mol Cell Biol 2006; 26: 3282-3294
61. Wang JY, Lin CH, Yang CH, Tan TH, Chen YR. Biochemical and biological characterization of a neuroendocrine-associated phosphatase. J Neurochem 2006; 98: 89-101
62. Li CJ, Lv L, Li H, Yu DM. Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol 2012; 11: 73
63. Esposito G, Prasad SV, Rapacciuolo A, Mao L, Koch WJ, Rockman HA. Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signalregulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload. Circulation 2001; 103: 1453-1458
64. Purcell NH, Wilkins BJ, York A, Saba-Leil MK, Meloche S, Robbins J et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 2007; 104: 14074-14079
65. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001; 103: 670-677
66. Kerkela R, Force T. p38 mitogen-activated protein kinase: a future target for heart failure therapy? J Am Coll Cardiol 2006; 48: 556-558
67. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007; 116: 1413-1423
68. Marber MS, Rose B, Wang Y. The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol 2011; 51: 485-490
69. Bi L, Chiang JY, Ding WX, Dunn W, Roberts B, Li T. Saturated fatty acids activate ERK signaling to downregulate hepatic sortilin 1 in obese and diabetic mice. J Lipid Res 2013; 54: 2754-2762
70. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-1274
71. Listenberger LL, Ory DS, Schaffer JE. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 2001; 276: 14890-14895